Predicting the risk of rethrombosis and hemorrhage in cancer patients with venous thromboembolism (VTE) poses a considerable challenge. The wide range of individual differences in this population makes both complications critical milestones during the ‘cancer journey’ [1]. Low molecular weight heparin (LMWH) was once the single established treatment for cancer-associated thrombosis. Nonetheless, direct oral anticoagulants (DOACs) have emerged as a promising alternative that simplifies therapy. Although the risk of recurrent thrombosis or major bleeding in patients is undeniably linked to unpredictable and unquantifiable events, like missed doses, temporary treatment interruption for an endoscopy, unintended telangiectasia rupture, etc., these factors do not impede the broader modeling of these endpoints to achieve a thorough understanding.
